hPDL1/B16-F10
CBPG0060
詢 價(jià)
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
I. Background | |||
Programmed Cell Death Protein 1(PD-1) ,一種在激活的 T 細(xì)胞上表達(dá)的受體,與其 配體 PD-L1 和 PD-L2 結(jié)合,負(fù)向調(diào)節(jié)免疫反應(yīng)。 PD-1 配體存在于大多數(shù)癌癥中,PD- 1:PD-L1/2 相互作用會(huì)抑制 T 細(xì)胞活性,并使癌細(xì)胞逃避免疫監(jiān)視。 PD1/PDL1 信號(hào)轉(zhuǎn)導(dǎo)通 路是腫瘤免疫抑制的重要組成部分,可以抑制 T 淋巴細(xì)胞的興奮,增強(qiáng)腫瘤細(xì)胞的免疫耐 受,從而實(shí)現(xiàn)腫瘤免疫逃逸。PD1 與 PDL1 結(jié)合可以減弱 T 細(xì)胞介導(dǎo)的免疫監(jiān)視,導(dǎo)致免 疫反應(yīng)缺失,甚至導(dǎo)致 T 細(xì)胞凋亡。PD1/PDL1 抑制劑可解除抗腫瘤 T 細(xì)胞的免疫抑制, 從而導(dǎo)致 T 細(xì)胞增殖并滲透到腫瘤微環(huán)境中并誘導(dǎo)抗腫瘤反應(yīng)。PD-1:PD-L1/2 通路還參與 調(diào)節(jié)自身免疫反應(yīng),使這些蛋白質(zhì)成為多種癌癥以及多發(fā)性硬化癥、關(guān)節(jié)炎、狼瘡和 I 型 糖尿病的有希望的治療靶點(diǎn)。 | |||
II. Introduction | |||
Host Cell: | B16-F10 | ||
Expressed gene: | hPDL1 | ||
Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) | ||
Freeze Medium: | 90% FBS+10% DMSO | ||
Culture Medium: | DMEM+10%FBS+5 μg/ml blasticdin | ||
Mycoplasma Testing: | Negative | ||
Storage: | Liquid nitrogen | ||
III. Description of Host Cell Line | |||
Organism: | Mus musculus, mouse | ||
Tissue: | skin | ||
Morphology: | mixture of spindle-shaped and epithelial-like cells | ||
Growth Properties: | adherent | ||
IV. Representative Data | |||
Figure 1. Recombinant hPDL1/B16-F10 stably expressing hPDL1. |
|||